Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Multiple Myeloma 12Lymphoma, Non-Hodgkin 7Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Recurrence 3Melanoma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Lymphoma, Follicular 2Cytokine Release Syndrome 2Craniopharyngioma 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × tocilizumab × 1 year × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡